These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 9694774)

  • 1. Anticoagulation may be beneficial in high risk factor V Leiden carriers.
    Baglin T; Baglin C; Brown K; Luddington R
    BMJ; 1998 Aug; 317(7155):416. PubMed ID: 9694774
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden--cost-effectiveness analysis.
    Marchetti M; Pistorio A; Barosi G
    Thromb Haemost; 2000 Nov; 84(5):752-7. PubMed ID: 11127850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of ischemic colitis associated with factor V Leiden mutation: successful treatment with anticoagulation.
    Chin BW; Greenberg D; Wilson RB; Meredith CG
    Gastrointest Endosc; 2007 Aug; 66(2):416-8. PubMed ID: 17524402
    [No Abstract]   [Full Text] [Related]  

  • 4. Should female relatives of factor V Leiden carriers be screened prior to oral contraceptive use? A cost-effectiveness analysis.
    Smith KJ; Monsef BS; Ragni MV
    Thromb Haemost; 2008 Sep; 100(3):447-52. PubMed ID: 18766261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of factor V Leiden mutation on duration of anticoagulation after a single thromboembolic event.
    Rintelen C; Pabinger I; Lechner K; Mannhalter C
    Thromb Haemost; 1997 Feb; 77(2):405. PubMed ID: 9157606
    [No Abstract]   [Full Text] [Related]  

  • 6. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.
    Ruggeri M; Gisslinger H; Tosetto A; Rintelen C; Mannhalter C; Pabinger I; Heis N; Castaman G; Missiaglia E; Lechner K; Rodeghiero F
    Am J Hematol; 2002 Sep; 71(1):1-6. PubMed ID: 12221665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia.
    Martinelli I; Legnani C; Bucciarelli P; Grandone E; De Stefano V; Mannucci PM
    Thromb Haemost; 2001 Sep; 86(3):800-3. PubMed ID: 11583310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: Response to warfarin.
    Davis MD; Wysokinski WE
    J Am Acad Dermatol; 2008 Mar; 58(3):512-5. PubMed ID: 18280355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early postoperative obstructive prosthetic mitral valve thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation.
    De Paulis S; Rossi E; Zamparelli R; Scapigliati A; Corrado M; De Stefano V
    Thromb Haemost; 2008 Feb; 99(2):441-2. PubMed ID: 18278197
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of thrombophilia in deciding on the duration of anticoagulation.
    Bauer KA
    Semin Thromb Hemost; 2004 Dec; 30(6):633-7. PubMed ID: 15630669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. East Anglian Thrombophilia Study Group.
    Baglin C; Brown K; Luddington R; Baglin T
    Br J Haematol; 1998 Mar; 100(4):764-8. PubMed ID: 9531346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
    Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leg ulcers associated with factor V Leiden and prothrombin G20210A and methyltetrahydrofolate reductase mutations: successful treatment with warfarin.
    Clivati Brandt HR; de Lorenzo Messina MC; Belda Júnior W; Costa Martins JE; Criado PR
    Int J Dermatol; 2007 Dec; 46(12):1319-20. PubMed ID: 18173539
    [No Abstract]   [Full Text] [Related]  

  • 14. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
    Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
    Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral thrombosis associated with heterozygous factor V Leiden mutation and high lipoprotein(a) level in a girl with factor XIII deficiency.
    Akbalik M; Duru F; Fisgin T; Tasdemir HA; Incesu L; Albayrak D; Ozyurek E
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):371-4. PubMed ID: 17473580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to decide on the optimal duration of anticoagulatn therapy in carriers of the factor V Leiden mutation.
    Middeldorp S; Büller HR
    Thromb Haemost; 2000 Nov; 84(5):740-1. PubMed ID: 11127847
    [No Abstract]   [Full Text] [Related]  

  • 17. Recurrent venous thrombosis with factor V Leiden mutation.
    Meenakshi-Sundaram S; Sridhar R; Jithendrian JJ; Durai RN; Arunkumar MJ; Sundar B
    J Assoc Physicians India; 2005 Jul; 53():642-4. PubMed ID: 16190136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of fetal loss in family members of probands with factor V Leiden mutation.
    Tormene D; Simioni P; Prandoni P; Luni S; Innella B; Sabbion P; Girolami A
    Thromb Haemost; 1999 Oct; 82(4):1237-9. PubMed ID: 10544905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A young patient with chronic recurrent leg ulcers; hyperhomocysteinemia and heterozygote for factor V Leiden].
    Kolbach DN; Boer J
    Ned Tijdschr Geneeskd; 1998 Dec; 142(49):2706-7. PubMed ID: 10094656
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.